Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Oncologist ; 27(2): e133-e141, 2022 03 04.
Artigo em Inglês | MEDLINE | ID: mdl-35641214

RESUMO

BACKGROUND: Geriatric assessment (GA) is recommended for evaluating fitness of an older adult with cancer. Our objective was to prospectively evaluate the gaps that exist in the assessment of older adults with metastatic breast cancer (OA-MBC) in community practices (CP). METHODS: Self-administered GA was compared to provider's assessment (PA) of patients living with MBC aged ≥65 years treated in CP Providers were blinded to the GA results until PA was completed. McNemar's test was used to detect differences between PA and GA. RESULTS: One hundred patients were enrolled across 9 CP (median age 73.9). Geriatric assessment detected a total of 356 abnormalities in 96 patients; of which, 223 required interventions. African American and widowed/single patients were more likely to have abnormalities identified by GA. On average, across 100 patients, PA did not detect 25.5% of GA-detected abnormalities, mostly in functional status, social support, nutrition, and cognition. These differences were less pronounced among providers with more clinical experience. Patients with abnormal Timed Up and Go tests more likely had additional abnormalities in other domains, and more abnormalities that were not identified by PA. Providers were "surprised" by GA results in 33% of cases, mainly with cognitive or social support findings, and reported plans for management change for 39% of patients based on GA findings. CONCLUSIONS: Including a GA in the care of OA-MBC in CP is beneficial for the detection of multiple abnormalities not detected by routine PA.


Assuntos
Neoplasias da Mama , Avaliação Geriátrica , Idoso , Neoplasias da Mama/diagnóstico , Feminino , Avaliação Geriátrica/métodos , Humanos , Programas de Rastreamento , Estudos Prospectivos , Apoio Social
2.
J Cancer Educ ; 27(4): 774-9, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22806216

RESUMO

Treating cancer in patients with concurrent severe mental illness is complex and challenging for patients, families, and health care providers. Two such illnesses include schizophrenia and bipolar disorder. In this review, cases of women with breast cancer and severe mental illness from Philadelphia, PA illustrate the obstacles these women face in maintaining adequate cancer care. Barriers to receiving cancer treatment include understanding their disease, continuing medications and appointments, and experiencing complications of their psychiatric disorders. Learning from these cases is critical for health care providers and allows for innovation in treating and educating this difficult population. Increasing patient visit time, using social support services, and psychiatrist and psychiatrist-liaisons are necessary to improve care. In addition, family or caregivers should be included in discussions when possible. These techniques will assist in educating patients, improve insight into their disease and treatment, and allow them to benefit from cancer therapy.


Assuntos
Transtorno Bipolar/terapia , Neoplasias da Mama/terapia , Cuidadores , Administração dos Cuidados ao Paciente , Esquizofrenia/terapia , Idoso , Transtorno Bipolar/complicações , Transtorno Bipolar/psicologia , Neoplasias da Mama/complicações , Neoplasias da Mama/psicologia , Feminino , Comportamentos Relacionados com a Saúde , Promoção da Saúde , Humanos , Pessoa de Meia-Idade , Cooperação do Paciente , Philadelphia , Esquizofrenia/complicações
3.
Leuk Res ; 32(12): 1820-3, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18468682

RESUMO

Adjuvant chemotherapy and radiation therapy for breast cancer are associated with therapy-related acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS), but little is known about additional risk factors. Thirty-four patients with AML (n=26)/MDS (n=8) following breast cancer (cases) were compared with 2029 breast cancer patients without AML/MDS (controls). Cases were older at breast cancer diagnosis (mean 60.2 years versus 54.5 years; p=0.01) and more commonly had additional cancers (29% versus 4.9%; p<0.0001) and >or=4 first-degree relatives with any type of cancer (OR: 5.37, CI: 1.44-19.9). Thus risk factors for AML/MDS following breast cancer include older age, other cancers and multiple first-degree relatives with cancer.


Assuntos
Neoplasias da Mama/complicações , Leucemia Mieloide Aguda/epidemiologia , Síndromes Mielodisplásicas/epidemiologia , Segunda Neoplasia Primária/epidemiologia , Neoplasias/complicações , Neoplasias da Mama/genética , Família , Feminino , Humanos , Leucemia Mieloide Aguda/genética , Masculino , Pessoa de Meia-Idade , Síndromes Mielodisplásicas/genética , Segunda Neoplasia Primária/genética , Núcleo Familiar
4.
Chemosphere ; 69(2): 262-70, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17544053

RESUMO

Investigations were carried out in batch modes for studying the immobilization behavior of polyphenol oxidase (PPO) on two different mesoporous activated carbon matrices, MAC400 and MAC200. The PPO was immobilized onto MAC400 and MAC200 at various enzyme activities 5 x 10(4), 10 x 10(4), 20 x 10(4), 30 x 10(4)Ul(-1), at pH 5-8, and at temperature ranging from 10 to 40 degrees C. The intensity of immobilization of PPO increased with increase in temperature and initial activities, while it decreased with increase in pH. Immobilization onto MAC400 followed the Langmuir model while Langmuir and Freundlich models could fit MAC200 data. Non-linear pseudo first order, pseudo second order and intraparticle diffusion models were evaluated to understand the mechanism of immobilization. The free and immobilized enzyme kinetic parameters (K(m) and V(max)) were determined by Michaelis-Menten enzyme kinetics. The K(m) values for free enzyme, PPO immobilized in MAC400 and in MAC200 were 0.49, 0.41 and 0.65 mM, respectively. The immobilization of PPO in carbon matrices was confirmed using FT-IR spectroscopy and scanning electron microscopy.


Assuntos
Carbono/metabolismo , Catecol Oxidase/metabolismo , Enzimas Imobilizadas/metabolismo , Adsorção , Concentração de Íons de Hidrogênio , Cinética , Microscopia Eletrônica de Varredura , Espectroscopia de Infravermelho com Transformada de Fourier , Termodinâmica
5.
Oncology (Williston Park) ; 20(6): 579-87; discussion 588, 594, 596 passim, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16773844

RESUMO

Carcinoembryonic antigen (CEA) monitoring in patients with stage I-IV colorectal cancer has been, and remains, a controversial issue in oncology practice. Recommendations vary from bimonthly monitoring to no monitoring in the surveillance setting (for stage I-III disease). In the metastatic setting, there are no clear guidelines for CEA follow-up, although continued monitoring in such patients is common in the oncology community. This manuscript reviews the accuracy of CEA testing, its value as a prognostic indicator, and its role in surveillance and response assessment. The limitations of the test in the adjuvant and metastatic settings are illustrated through several case reports from the Colorectal Oncology Clinic at Roswell Park Cancer Institute. Guidelines for CEA monitoring are provided, based on a detailed literature review and institutional experience.


Assuntos
Antígeno Carcinoembrionário/análise , Neoplasias Colorretais/diagnóstico , Oncologia/normas , Recidiva Local de Neoplasia/diagnóstico , Neoplasias Colorretais/patologia , Neoplasias Colorretais/prevenção & controle , Neoplasias Colorretais/cirurgia , Análise Custo-Benefício , Testes Diagnósticos de Rotina , Humanos , Programas de Rastreamento , Recidiva Local de Neoplasia/prevenção & controle , Estadiamento de Neoplasias , Guias de Prática Clínica como Assunto , Prognóstico , Sensibilidade e Especificidade , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...